nach oben

Erschienen in:

10.06.2017 | Article

Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes

verfasst von: Nicolae M. Panduru, Carol Forsblom, Markku Saraheimo, Lena M. Thorn, Daniel Gordin, Nina Elonen, Valma Harjusalo, Angelika Bierhaus, Per M. Humpert, Per-Henrik Groop, on behalf of the FinnDiane Study Group

Erschienen in: Diabetologia | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

In type 1 diabetes, cardiovascular disease (CVD) and diabetic nephropathy progress in parallel, thereby potentiating the risk of premature death during their development. Since urinary liver-type fatty acid binding protein (L-FABP) predicts the progression of diabetic nephropathy, the aim of this study was to investigate whether urinary L-FABP also predicts cardiovascular outcomes and mortality.

Methods

We tested our hypothesis in a Finnish cohort of 2329 individuals with type 1 diabetes and a median follow-up of 14.1 years. The L-FABP to creatinine ratio was determined from baseline urine samples. The predictive value of urinary L-FABP was evaluated using Cox regression models, while its added predictive benefit for cardiovascular outcomes and mortality was evaluated using a panel of statistical indexes.

Results

Urinary L-FABP predicted incident stroke independently of traditional risk factors (HR 1.33 [95% CI 1.20, 1.49]) and after further adjustment for eGFR (HR 1.28 [95% CI 1.14, 1.44]) or AER (HR 1.24 [95% CI 1.06, 1.44]). In addition, it predicted mortality independently of traditional risk factors (HR 1.34 [95% CI 1.24, 1.45]), and after adjustment for eGFR (HR 1.29 [95% CI 1.18, 1.39]) or AER (HR 1.22 [95% CI 1.09, 1.36]). Urinary L-FABP was as good a predictor as eGFR or AER, and improved the AUC for both outcomes on top of traditional risk factors, with no reclassification benefit (integrated discrimination improvement/net reclassification improvement) for stroke or mortality when AER or eGFR were added to traditional risk factors. However, urinary L-FABP was not a predictor of other cardiovascular endpoints (coronary artery disease, peripheral vascular disease and overall CVD events) when adjusted for the AER.

Conclusions/interpretation

Urinary L-FABP is an independent predictor of stroke and mortality in individuals with type 1 diabetes.

Nur mit Berechtigung zugänglich

Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760–765CrossRefPubMed

Laing SP, Swerdlow AJ, Carpenter LM et al (2003) Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 34:418–421CrossRefPubMed

Maftei O, Pena AS, Sullivan T et al (2014) Early atherosclerosis relates to urinary albumin excretion and cardiovascular risk factors in adolescents with type 1 diabetes: Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT). Diabetes Care 37:3069–3075CrossRefPubMed

Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658CrossRefPubMedPubMedCentral

Forsblom C, Harjutsalo V, Thorn LM et al (2011) Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22:537–544CrossRefPubMedPubMedCentral

Thorn LM, Forsblom C, Waden J et al (2009) Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32:950–952CrossRefPubMedPubMedCentral

McKenna K, Thompson C (1997) Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scott Med J 42:99–104CrossRefPubMed

Viberti GC (1991) Diabetic renal disease in type 1 diabetes: aetiology and prevention. Diabet Med 8 Spec No:S38–S42CrossRefPubMed

Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno Hypothesis. Diabetologia 32:219–226

10.

Panduru NM, Forsblom C, Saraheimo M et al (2013) Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 36:2077–2083CrossRefPubMedPubMedCentral

11.

Makowski L, Hotamisligil GS (2005) The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 16:543–548CrossRefPubMedPubMedCentral

12.

Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7:489–503CrossRefPubMedPubMedCentral

13.

Kamijo-Ikemori A, Sugaya T, Kimura K (2006) Urinary fatty acid binding protein in renal disease. Clin Chim Acta 374:1–7CrossRefPubMed

14.

Matsui K, Kamijo-Ikemorif A, Sugaya T, Yasuda T, Kimura K (2011) Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am J Pathol 178:1021–1032CrossRefPubMedPubMedCentral

15.

Yamamoto T, Noiri E, Ono Y et al (2007) Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 18:2894–2902CrossRefPubMed

16.

Matsui K, Kamijo-Ikemori A, Imai N et al (2016) Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol 20:195–203CrossRefPubMed

17.

Ishimitsu T, Ohta S, Saito M et al (2005) Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol 9:34–39CrossRefPubMed

18.

Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P (2010) Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 33:1320–1324CrossRefPubMedPubMedCentral

19.

Araki S, Haneda M, Koya D et al (2013) Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care 36:1248–1253CrossRefPubMedPubMedCentral

20.

Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024CrossRefPubMed

21.

Stevens LA, Coresh J, Schmid CH et al (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51:395–406CrossRefPubMedPubMedCentral

22.

Sund R (2012) Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health 40:505–515CrossRefPubMed

23.

Gordin D, Forsblom C, Panduru NM et al (2014) Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 37:2593–2600CrossRefPubMed

24.

Delong ER, Delong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRefPubMed

25.

Pencina MJ, D’Agostino RB Sr, D’Agostino R Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172 discussion 207–212CrossRefPubMed

26.

Pencina MJ, D’Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11–21CrossRefPubMed

27.

Greenland P, Smith SC Jr, Grundy SM (2001) Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 104:1863–1867CrossRefPubMed

28.

Yamada Y, Kato K, Oguri M et al (2008) Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 21:801–808PubMed

29.

Fukuda Y, Miura S, Zhang B et al (2009) Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease. Intern Med 48:1731–1737CrossRefPubMed

30.

Matsumori R, Shimada K, Kiyanagi T et al (2012) Clinical significance of the measurements of urinary liver-type fatty acid binding protein levels in patients with acute coronary syndrome. J Cardiol 60:168–173CrossRefPubMed

31.

Pluznick J (2014) A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 5:202–207CrossRefPubMed

32.

Kamijo A, Sugaya T, Hikawa A et al (2004) Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 165:1243–1255CrossRefPubMedPubMedCentral

33.

Nosadini R, Tonolo G (2011) Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis 21:79–85CrossRefPubMed

34.

Inoue T, Ikeda H, Nakamura T et al (2011) Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med 50:1273–1278CrossRefPubMed

35.

Agarwal A, Balla J, Balla G, Croatt AJ, Vercellotti GM, Nath KA (1996) Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Phys 271:F814–F823

36.

Pelsers MM, Hanhoff T, Van Der Voort D et al (2004) Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 50:1568–1575CrossRefPubMed

37.

Wunderlich MT, Hanhoff T, Goertler M et al (2005) Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 252:718–724CrossRefPubMed

Titel: Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes
verfasst von: Nicolae M. Panduru
Carol Forsblom
Markku Saraheimo
Lena M. Thorn
Daniel Gordin
Nina Elonen
Valma Harjusalo
Angelika Bierhaus
Per M. Humpert
Per-Henrik Groop
on behalf of the FinnDiane Study Group
Publikationsdatum: 10.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 9/2017
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-017-4328-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes